Based on the PALOMA-1trail, FDA approved palbociclib, the first CDK 4/6 inhibitor, in combination with letrozole as first-line treatment for patients with ER-positive, HER2-negative advanced breast cancer (ABC) or metastatic breast cancer (MBC) (3). This evidence concerns the gene ESR1 and breast cancer.